Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Notes Due from Affiliates	Accumulated Deficit	Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2020		50,035,408
Beginning balance at Dec. 31, 2020	$ 64,189	$ 50	$ 196,852	$ (927)	$ (131,786)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		126,497
Exercise of stock options	498		498
Vesting of restricted stock units (in shares)		109,482
Taxes paid related to net settlement of equity awards	(586)		(586)
Stock-based compensation expense	2,199		2,199
Interest accrued relating to notes due from affiliates	(9)			(9)
Net loss	(3,852)				(3,852)
Ending balance (in shares) at Mar. 31, 2021		50,271,387
Ending balance at Mar. 31, 2021	62,439	$ 50	198,963	(936)	(135,638)
Beginning balance (in shares) at Dec. 31, 2020		50,035,408
Beginning balance at Dec. 31, 2020	64,189	$ 50	196,852	(927)	(131,786)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(18,670)
Change in foreign currency translation adjustment	0
Ending balance (in shares) at Sep. 30, 2021		52,012,032
Ending balance at Sep. 30, 2021	68,756	$ 51	220,106	(945)	(150,456)
Beginning balance (in shares) at Mar. 31, 2021		50,271,387
Beginning balance at Mar. 31, 2021	62,439	$ 50	198,963	(936)	(135,638)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		287,745
Exercise of stock options	790		790
Vesting of restricted stock units (in shares)		169,915
Taxes paid related to net settlement of equity awards	(1,249)		(1,249)
Stock-based compensation expense	2,941		2,941
Interest accrued relating to notes due from affiliates	(6)			(6)
Net loss	(6,804)				(6,804)
Ending balance (in shares) at Jun. 30, 2021		50,729,047
Ending balance at Jun. 30, 2021	58,111	$ 50	201,445	(942)	(142,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		350,394
Exercise of stock options	935		935
Exercise of warrants (in shares)		37,410
Exercise of warrants			0
Vesting of restricted stock units (in shares)		129,448
Taxes paid related to net settlement of equity awards	(1,334)		(1,334)
Issuance of warrants with convertible note	844		844
Beneficial conversion feature associated with convertible note	603		603
Issuance of common stock in connection with an acquisition (in shares)		765,733
Issuance of common stock in connection with an acquisition	13,821	$ 1	13,820
Vested option awards assumed in connection with an acquisition	533		533
Stock-based compensation expense	3,260		3,260
Interest accrued relating to notes due from affiliates	(3)			(3)
Net loss	(8,014)				(8,014)
Change in foreign currency translation adjustment	0
Ending balance (in shares) at Sep. 30, 2021		52,012,032
Ending balance at Sep. 30, 2021	$ 68,756	$ 51	220,106	(945)	(150,456)
Beginning balance (in shares) at Dec. 31, 2021	60,221,799	60,221,799
Beginning balance at Dec. 31, 2021	$ 250,045	$ 61	416,278	(951)	(165,343)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		277,995
Exercise of stock options	1,508		1,508
Exercise of warrants (in shares)		66,892
Vesting of restricted stock units (in shares)		124,059
Taxes paid related to net settlement of equity awards	(716)		(716)
Issuance of common stock	85		85
Issuance of common stock in connection with an acquisition (in shares)		779,032
Issuance of common stock in connection with an acquisition	15,409	$ 1	15,408
Stock-based compensation expense	6,095		6,095
Interest accrued relating to notes due from affiliates	(5)			(5)
Net loss	(25,222)				(25,222)
Change in foreign currency translation adjustment	29					29
Ending balance (in shares) at Mar. 31, 2022		61,469,777
Ending balance at Mar. 31, 2022	$ 247,228	$ 62	438,658	(956)	(190,565)	29
Beginning balance (in shares) at Dec. 31, 2021	60,221,799	60,221,799
Beginning balance at Dec. 31, 2021	$ 250,045	$ 61	416,278	(951)	(165,343)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	393,378
Net loss	$ (79,326)
Change in foreign currency translation adjustment	$ (14)
Ending balance (in shares) at Sep. 30, 2022	62,284,507	62,284,507
Ending balance at Sep. 30, 2022	$ 215,462	$ 62	460,395	(312)	(244,669)	(14)
Beginning balance (in shares) at Mar. 31, 2022		61,469,777
Beginning balance at Mar. 31, 2022	247,228	$ 62	438,658	(956)	(190,565)	29
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		56,583
Exercise of stock options	258		258
Exercise of warrants (in shares)		20,903
Exercise of warrants	1		1
Vesting of restricted stock units (in shares)		179,118
Taxes paid related to net settlement of equity awards	(778)		(778)
Stock-based compensation expense	10,429		10,429
Interest accrued relating to notes due from affiliates	(3)			(3)
Repayment of notes due from affiliates	1,296		648	648
Issuance of common stock in settlement of contingent consideration (in shares)		360,724
Issuance of common stock in settlement of contingent consideration	4,221		4,221
Net loss	(32,985)				(32,985)
Change in foreign currency translation adjustment	(14)					(14)
Ending balance (in shares) at Jun. 30, 2022		62,087,105
Ending balance at Jun. 30, 2022	229,653	$ 62	453,437	(311)	(223,550)	15
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		58,800
Exercise of stock options	228		228
Vesting of restricted stock units (in shares)		214,522
Taxes paid related to net settlement of equity awards	(1,233)		(1,233)
Stock-based compensation expense	7,963		7,963
Interest accrued relating to notes due from affiliates	(1)			(1)
Cancellation of revesting stock (in shares)		(75,920)
Net loss	(21,119)				(21,119)
Change in foreign currency translation adjustment	$ (29)					(29)
Ending balance (in shares) at Sep. 30, 2022	62,284,507	62,284,507
Ending balance at Sep. 30, 2022	$ 215,462	$ 62	$ 460,395	$ (312)	$ (244,669)	$ (14)